Radiopharm Theranostics Limited

Radiopharm Theranostics Limited (NASDAQ : RADX) is a clinical-stage radiotherapeutics company focused on developing radiopharmaceuticals for both diagnosis and therapy in indications with high unmet medical need, including brain metastases, HER2-positive breast cancer, non-small cell lung cancer, pancreatic cancer, prostate cancer, and glioblastoma. Its diversified pipeline spans paired diagnostic–therapeutic agents such as pivalate-based RAD101/102, Nano-mAb HER2 and PDL1 programs, Avß6-integrin assets, PSA-targeted prostate candidates, and PTPµ-targeted glioblastoma products. Founded in 2021 and headquartered in Carlton, Australia, Radiopharm also benefits from a strategic development agreement with Lantheus Holdings.

Key Business Updates:

Radiopharm Reports 92% Interim Success in RAD 101 Brain Metastases Imaging
Radiopharm Theranostics has reported encouraging interim data from its Phase 2b trial evaluating RAD 101, an imaging agent targeting brain metastases from solid tumours. In the first 12 evaluable patients, 92% achieved concordance between RAD 101 PET imaging and MRI, meeting the study’s primary endpoint and supporting the agent’s diagnostic potential in detecting brain metastases. This suggests a meaningful commercial opportunity if future data remain supportive, with management and external commentary pointing to a potential U.S. market exceeding several hundred million dollars annually for brain metastasis imaging.​

However, this readout remains an early interim analysis based on a very small cohort, with the trial only around half enrolled and a pivotal study not expected to start until approximately 2026, implying that further validation, larger datasets and regulatory review will be required before RAD 101 can be commercialized.

Short-Term Technical View: Cautiously Bullish Bias

• Price has repeatedly held a strong horizontal support zone around 3.6–4.0, indicating persistent dip‑buying interest and suggesting this area is perceived as value.

• The latest rebound from this support, with price now stabilising above it near 4.2, points to a potential short‑term base rather than a fresh downside breakdown.
• The 14‑day RSI has turned up from near oversold territory into the low‑40s, signalling fading downside momentum and room for a constructive momentum shift if the move extends.
• As long as the stock remains above the identified support band, the technical setup leans cautiously bullish, with scope for a recovery toward previous swing levels around 5–6 while using the support zone as a clear stop‑loss reference.

Radiopharm Theranostics presents a high‑risk, high‑reward opportunity underpinned by both clinical and technical factors. Interim Phase 2b data for RAD 101 in recurrent brain metastases demonstrated 92% concordance with MRI in 11 of 12 evaluable patients, meeting the primary endpoint and, together with FDA fast‑track status, partially de‑risking the lead asset. The share price has repeatedly respected support in the USD 3.60–4.00 range and has recently rebounded, with RSI turning up from near‑oversold levels, indicating easing downside pressure. In light of this, a “Speculative Buy” rating is assigned to RADX at the closing price of USD 4.26 on 12 December 2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective, and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is December 12, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.